344 results on '"Hassel, Jessica C"'
Search Results
2. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
3. Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
4. Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level
5. The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
6. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
7. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
8. The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
9. Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action
10. Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma
11. Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma
12. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
13. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp
14. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
15. Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
16. Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
17. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
18. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
19. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
20. Bimodal intensity-modulated radiotherapy in combination with carbon ion therapy (C12) of mucosal melanomas - data of the last decade from Heidelberg University Hospital.
21. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
22. Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
23. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
24. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
25. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
26. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
27. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
28. Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).
29. T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.
30. Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease.
31. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
32. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
33. Melanoma brain metastases – Interdisciplinary management recommendations 2020
34. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
35. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
36. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature
37. Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial
38. Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study
39. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases
40. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma
41. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.
42. An Online Decision Aid for Patients With Metastatic Melanoma.
43. Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets.
44. Nebenwirkungen dermatoonkologischer Therapien.
45. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
46. Neues vom ASCO 2024 zum Melanom.
47. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
48. Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
49. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
50. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.